<DOC>
	<DOCNO>NCT00361582</DOCNO>
	<brief_summary>The purpose study evaluate patient eligible elective primary total partial joint replacement hip knee due chronic osteoarthritis efficacy ( level pain control ) CG5503 5 10 day compare placebo , assess safety tolerability multiple dos CG5503 IR patient .</brief_summary>
	<brief_title>A Study Evaluate Effectiveness Safety Multiple Doses Tapentadol ( CG5503 ) Patients Awaiting Joint Replacement Surgery</brief_title>
	<detailed_description>CG5503 centrally active pain-relieving drug investigate treatment acute chronic pain . This study design assess safety tolerability CG5503 IR patient need joint replacement hip knee due chronic osteoarthritis . This double-blind study , i.e. , neither patient investigator know treatment give . Before start 10 day double-blind phase , patient screen eligibility eligible patient randomly assign receive either CG5503 IR , oxycodone IR , placebo ( i.e. , active drug ) . All patient take treatment mouth every 4 6 hour wake hour . A total 60 dos ( 6 dos per day ) study treatment provide patient 10-day treatment phase . The study treatment dispense Day 1 , patient take first dose evening day . The effectiveness study treatment ( CG5503 IR , oxycodone , placebo ) assess use several measure , include 11 Point Pain Numerical Rating Scale , 5-Point Relief Numerical Rating Scale , Patient Global Impression Change . Using scale , patient indicate pain intensity level , pain relief level , overall status well-being . Safety tolerability assess use physical examination , monitor adverse event , clinical laboratory measure , 12 lead ECG result . The null hypothesis study CG5503 IR dosage efficacy result equal placebo base 5-day SPID treatment chronic pain cause osteoarthritis . The alternative study hypothesis least 1 CG5503 IR dose effect different placebo effect . CG5503 IR 50 mg , 75 mg base , 10 mg oxycodone placebo 10 day take mouth every 4 6 hour wake hour . Patients randomize CG5503 IR 75 mg group receive CG5503 IR 50 mg Day 1 75 mg Day 2 10 . All dos study treatment take approximately 120 mL water food .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Arthralgia</mesh_term>
	<criteria>Clinical diagnosis chronic osteoarthritis hip knee base clinical radiographic ( XRay ) criterion define standard accept guideline candidate ( qualifies ) primary onesided total partial joint replacement surgery due noninflammatory , endstage degenerative joint disease ( arthritis ) require daily dos analgesic medication chronic pain . History seizure disorder epilepsy suggest presence follow History chronic hepatitis B C human immunodeficiency virus , presence active hepatitis B C within past 3 month screen currently treat anticonvulsant , monoamine oxidase inhibitor , tricyclic antidepressant , neuroleptic , serotonin norepinephrine reuptake inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>tapentadol</keyword>
	<keyword>knee-replacement</keyword>
	<keyword>hip replacement</keyword>
	<keyword>pain</keyword>
</DOC>